Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease

Patent metadata

Field	Value
Publication number	US-11267780-B2
Application number	US-201917040832-A
Country	US
Kind code	B2
Filing date	Apr 30, 2019
Priority date	Apr 30, 2018
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

First claim

What is claimed is:

1. A method for modulating DDAH and asymmetric dimethylarginine (ADMA) in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound defined by Formula I:

or a pharmaceutically acceptable salt or prodrug thereof, wherein
represents a single, double, or triple bond;
X 1 and X 2 , as valence permits, are independently absent with one of X 1 and X 2 , being selected from C, CH, CH 2 , O, CO, S, SO 2 , and NR′ or both X 1 and X 2 , as valence permits, are independently selected from C, CH, CH 2 , O, CO, S, SO 2 , and NR′; wherein R′ is independently selected from hydrogen or C 1 -C 6 alkyl; or X 1 and X 2 together with the bond to which they are attached form a 3 or 4 membered carbocyclic ring;
R 2 is, independently for each occurrence, selected from halogen, cyano, hydroxyl, amino, alkylamino, dialkylamino, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, haloalkoxy carbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl;
n is an integer from 0 to 4;
Y is selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted with one or more substituents individually selected from R″; and
R″ is, independently for each occurrence, selected from fluoro, cyano, nitro, hydroxyl, amino, alkylamino, dialkylamino, nitrile, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxy carbonyl, haloalkoxy carbonyl, alkylaminocarbonyl, heteroalkylaminocarbonyl, dialkylaminocarbonyl, and heterodialkylaminocarbonyl, with the proviso that when R″ is hydroxyl, Y further comprises a second substituent.

2. The method of claim 1 , wherein Y is a substituted or unsubstituted aryl ring, optionally wherein Y is selected from an oxazole ring, a pyridinyl ring, a thiazole ring, and a thiophene ring.

3. The method of claim 1 , wherein said compound comprises the structure

(i) Z 1 selected from C and S; and
Z 2 is selected from C, N and S, wherein Z 1 and Z 2 are not both C; or

(ii) Z 1 is selected from C and N; and
Z 2 is selected from C, O and S, wherein Z 1 and Z 2 are not both C.

4. The method of claim 1 wherein said compound is defined by the formula:

or a pharmaceutically acceptable salt or prodrug thereof, wherein
represents a single, double, or triple bond;
X 1 and X 2 , as valence permits, are independently absent, with one of X 1 and X 2 , being selected from C, CH, CH 2 , O, CO, S, SO 2 , and NR′ or both X 1 and X 2 , as valence permits, are independently selected from C, CH, CH 2 , O, CO, S, SO 2 , and NR′; wherein R′ is independently selected from hydrogen or C 1 -C 6 alkyl; or X 1 and X 2 together with the bond to which they are attached form a 3 or 4 membered carbocyclic ring; and
R 3 , R 4 , R 5 , R 6 , and R 7 are independently selected from hydrogen, fluoro, cyano, nitro, hydroxyl, amino, alkylamino, dialkylamino, nitrile, alkyl, haloalkyl; alkylthio; haloalkylthio; alkoxy, haloalkoxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, haloalkylcarbonyl, alkoxycarbonyl, haloalkoxy carbonyl, with the proviso that when R 5 is hydroxyl, at least one of R 3 , R 4 , R 6 , and R 7 is other than hydrogen.

5. The method of claim 4 , wherein X 1 and X 2 are
i) both CH;
ii) independently O or CH 2 or
iii) together with the bond to which they are attached form a 3-membered carbocyclic ring.

6. The method of claim 1 , wherein said compound is defined by the formula:

or a pharmaceutically acceptable salt or prodrug thereof, wherein
R 1 , R 2 , R 3 , and R 4 , are independently selected from hydrogen and hydroxyl;
R 5 is selected from hydrogen, methyl and 2-(morpholin-4-yl)ethoxy;
R 6 , is selected from hydrogen and 2-(morpholin-4-yl)ethoxy; and
R 7 is selected from hydrogen, halogen, hydroxy, methoxy, and 2-(morpholin-4-yl)ethoxy.

7. The method of claim 1 , wherein X 1 and X 2 together with the bond to which they are attached forms a 3-membered carbocyclic ring.

8. The method of claim 1 wherein said composition is administered for treating or preventing a disease or condition associated with elevated levels of asymmetric dimethylarginine (ADMA) in a subject.

9. The method of claim 8 , wherein the risk factors, disease or condition includes hypertension, heart failure, pulmonary arterial hypertension, erectile dysfunction, coronary and peripheral arterial disease, renal disease, insulin resistance, diabetes, atrial fibrillation, sickle cell disease, organ damage, sepsis, renal failure, endothelial dysfunction, vascular disease, or a combination thereof.

10. The method of claim 1 wherein said composition is administered for reducing fibrosis in a cell or tissue.

11. The method of claim 10 , wherein the fibrotic condition is a fibrotic condition of the lung, a fibrotic condition of the liver, a fibrotic condition of the heart or vasculature, a fibrotic condition of the kidney, a fibrotic condition of the skin, a fibrotic condition of the gastrointestinal tract, a fibrotic condition of the bone marrow or hematopoietic tissue, a fibrotic condition of the nervous system, or a combination thereof.

12. The method of claim 11 , wherein the fibrotic condition a fibrotic condition of the lung.

13. The method of claim 12 , wherein the fibrotic condition of the lung is chosen from one or more of: pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonitis (UIP), interstitial lung disease, cryptogenic fibrosing alveolitis (CFA), or bronchiectasis.

14. The method of claim 1 wherein said composition is administered for treating a disease associated with elevated levels of DDAH in a subject in need thereof.

15. The method of claim 14 , wherein the disease associated with elevated levels of DDAH comprises pain, diabetic retinopathy, cancer, or a combination thereof.

16. A compound defined by the general structure:

or a pharmaceutically acceptable salt or prodrug thereof, wherein
is a single, double, or triple bond;
X 1 and X 2 as valence permits, are independently absent, with one of X 1 and X 2 , being selected from C, CH, C 2 , O, CO, S, SO 2 , and NR′ or both X 1 and X 2 , as valence permits, are independently selected from C, CH, CH 2 , O, CO, S, SO 2 , and NR′; wherein R is independently selected from hydrogen or C 1 -C 6 alkyl; or X 1 and X 2 together with the bond to which they are attached form a 3 or 4 membered carbocyclic ring.

17. The method of claim 1 , wherein said compound is selected f

Assignees

• The Trustees Of Indiana Univerity
• Univ Indiana Trustees

Inventors

• Singh Jaipal
• Fowler Kerry

Classifications

• C07C65/19 Primary

  having unsaturation outside the aromatic ring · CPC title

• A61K31/192 Primary

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• C12N9/0075

  Nitric-oxide synthase (1.14.13.39) · CPC title

• C07D295/088

  to an acyclic saturated chain · CPC title

• C07C63/49

  containing rings other than six-membered aromatic rings · CPC title